First Merchants Corp bought a new position in shares of Allergan PLC. (NYSE:AGN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,900 shares of the company’s stock, valued at approximately $389,000.

A number of other institutional investors and hedge funds also recently modified their holdings of AGN. Hudock Capital Group LLC lifted its holdings in shares of Allergan PLC. by 0.4% in the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after purchasing an additional 2 shares in the last quarter. Burns J W & Co. Inc. NY lifted its stake in shares of Allergan PLC. by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the period. Pacific Center for Financial Services lifted its stake in shares of Allergan PLC. by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after buying an additional 7 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Allergan PLC. by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after buying an additional 9 shares during the period. Finally, Trust Co lifted its stake in shares of Allergan PLC. by 0.8% during the first quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the period. Institutional investors own 82.14% of the company’s stock.

Several equities research analysts have recently issued reports on AGN shares. Citigroup Inc. reissued a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 20th. Piper Jaffray Companies set a $227.00 price objective on shares of Allergan PLC. and gave the stock a “hold” rating in a research report on Friday, October 6th. Deutsche Bank AG set a $251.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Royal Bank Of Canada reissued a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, Wells Fargo & Company set a $276.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $245.73.

TRADEMARK VIOLATION NOTICE: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/first-merchants-corp-buys-new-stake-in-allergan-plc-agn/1683093.html.

Shares of Allergan PLC. (NYSE:AGN) opened at $174.84 on Monday. The company has a market capitalization of $58,175.43, a P/E ratio of 11.34, a PEG ratio of 0.93 and a beta of 1.13. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. Allergan PLC. has a twelve month low of $169.64 and a twelve month high of $256.80.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the firm posted $3.32 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. analysts forecast that Allergan PLC. will post 16.27 earnings per share for the current year.

Allergan PLC. declared that its board has authorized a stock repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.60%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is -12.44%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.